Relmada Therapeutics, Inc. (RLMD)
Relmada Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Coral Gables, FL, US. The stock last traded at $4.55, up 1.79% on the session, giving a market capitalisation of $477.2M. On trailing twelve-month figures it carries a trailing P/E of -4.95, a net margin of 0.0%. Its beta of 0.48 implies it has historically moved less than the broad market.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Relmada Therapeutics, Inc. is most often compared with the following Healthcare names: